Robert Charles Breedlove - 16 Jul 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: Principal Accounting Officer
Signature: /s/ Steven Basta, Attorney-in-Fact for Robert Charles Breedlove
Issuer symbol: PHAT
Transactions as of: 16 Jul 2025
Net transactions value: -$14,152
Form type: 4
Filing time: 18 Jul 2025, 16:05:07 UTC
Previous filing: 21 May 2025
Next filing: 09 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Breedlove Robert Charles	Principal Accounting Officer	C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK	/s/ Steven Basta, Attorney-in-Fact for Robert Charles Breedlove	18 Jul 2025	0002066645

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Sale	$14,152	-1,692	-3.4%	$8.36	48,392	16 Jul 2025	Direct	F1, F2
holding	PHAT	Common Stock						5,108	16 Jul 2025	By 401(k)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in mutliple transactions at prices $8.364 and $8.35. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in mutliple transactions at prices $8.364 and $8.35. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.